Brief: 180 Life Sciences Corp Scheduled Meeting During Q4 2022 With MHRA Regarding its Phase 2B Data In Dupuytren’S Disease

Forum Markets,

26/09/2022 13:56

Sept 26 (Reuters) - 180 Life Sciences Corp  ATNF.O :
    * 180 LIFE SCIENCES CORP - SCHEDULED MEETING DURING Q4 2022
WITH
MHRA REGARDING OUR PHASE 2B DATA IN DUPUYTREN’S DISEASE
    * 180 LIFE SCIENCES CORP - WE EXPECT TO GAIN CLARITY FROM
THE MHRA
BY LATE FIRST QUARTER OF 2023

Further company coverage:  ATNF.O 
 ((Reuters.Briefs@thomsonreuters.com;;))